The ravaging effects of cognitive decline from behavior-related chronic diseases take an enormous toll on families and communities. Apollo Health understands this battle, providing invaluable medical information needed to “flip the script” and disrupt the inevitability of cognitive decline.
Our leadership team brings diverse experiences and expertise to this challenge, while our technology streamlines the journey each of our community members embarks on to manage their brain health while providing vital information and analysis to the practitioner.
James F. Brown has been the CEO of Apollo Health (previously known as AHNP Precision Health) since January, 2019. He also serves as a board member and chairman of Bellicum Pharmaceuticals. Previously, James was a managing director of AVG Ventures, a private investment firm.
James was an Executive Vice President, General Manager of OpenTV, a technology and media company. As EVP he managed the company’s applications business unit before its sale to Liberty Media. James was a partner at the law firms McDermott, Will & Emery and Pillsbury Madison & Sutro. He obtained his bachelor of science in accounting from Weber State University and his law degree from the Brigham Young University School of Law.
Lance Kelly has over 25 years of experience leading engineering and design teams focused on consumer technology. His executive management track record has multiple examples of delivering innovative and successful products even in challenging markets.
Before co-founding Apollo Health as COO and co-chair, he held senior management positions in product development at Apple Computer, Exodus Communications, Centrata, and ePlay.
Additionally, Lance served as Chief of Studio Operations at Total Entertainment Network and Vice President of Software Engineering and Operations for Pogo.com where he was also a co-founder. Both Pogo.com and Centrata were KPCB companies funded by Vinod Khosla. Mr. Kelly led Pogo.com’s product development team from its inception to create an industry-leading user experience which led to the company’s acquisition by Electronic Arts.
Dale Bredesen, MD
Chief Science Officer – Brain Health
is a neuroscientist and neurologist, professor and author in the field of neurodegenerative diseases. He was the founding President and CEO of the Buck Institute for Research on Aging, and his laboratory research over 30 years has focused on the mechanisms underlying neurodegenerative diseases such as Alzheimer’s, leading to the first successful reversals of cognitive decline in Alzheimer’s disease, published in 2014, 2016, and 2018. Dr. Bredesen is a prodigious innovator in medicine, with over 30 patents to his name. Some of his over 220 scholarly publications and case studies include:
Reversal of Cognitive Decline: 100 Patients describes 100 patients, treated by several different physicians trained in the ReCODE protocol, with documented improvement in cognition, in some cases with documentation of improvement in electrophysiology or imaging as well. This additional report provides further support for a randomized, controlled clinical trial of the protocol and the overall approach. (Journal of Alzheimer’s Disease and Parkinsonism 2018)
Reversal of cognitive decline in Alzheimer’s disease and Reversal of cognitive decline: a novel therapeutic program gave the first descriptions of the reversal of cognitive decline in patients with early Alzheimer’s disease or its precursors, MCI (mild cognitive impairment) and SCI (subjective cognitive impairment). (Impact Journals: Aging 2014 and 2016)
Transcriptional Effects of ApoE4: Relevance to Alzheimer’s Disease explained how ApoE4 acts as a transcription factor and binds to the promoters of genes involved in a range of processes linked to aging and AD disease pathogenesis. These findings point to novel therapeutic strategies for AD and aging, resulting in an extension of human healthspan, the disease-free and functional period of life. (Molecular Neurobiology 2018)
Dr. Bredesen put much of his research and translation into the 2017 New York Times bestseller The End of Alzheimer’s: The First Program to Prevent and Reverse Cognitive Decline, which is now available in 30 different languages.
After graduating from Caltech and earning his MD from Duke University, he was the Chief Resident in Neurology at the University of California, San Francisco (UCSF). While at UCSF he joined Nobel Laureate Prof. Stanley Prusiner’s laboratory, and was later appointed to his Institute for Neurodegenerative Diseases.
Dr. Bredesen currently holds a faculty position at UCLA and is Professor Emeritus at the Buck Institute for Research on Aging. He joined the Buck Institute in 1998 as the founding President and CEO. He previously held faculty positions at the University of California, San Francisco, and University of California, San Diego.
Christine Coward, MSW, PCC
Christine “Chris” Coward has a background in clinical social work and has been coaching since 2004. In 1991, she obtained her MSW in Social Work at the University of North Carolina at Chapel Hill. Chris is Vice President of Coaching Services for Apollo Health, running the HabitChange business unit. In 2009 while at Neumann University she co-developed and taught a 125-hour coach-training program that evolved into HabitChange. Since 2009, HabitChange has been credentialed and accredited by the International Coach Federation (ICF).
Chris works closely with Dr. Bredesen as an evangelist and coach for participants of the ReCODE Program to reverse cognitive impairment. She is a member of the ICF and formerly served on the board for the Philadelphia Area Coach Alliance. Chris is currently the President-Elect of ICF’s Colorado chapter.